Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28- T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer.
CD8+ T lymphocytes
exhaustion
head-neck cancer
regulatory T cells
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 May 2021
06 May 2021
Historique:
received:
23
02
2021
revised:
13
04
2021
accepted:
27
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Head and neck squamous cell carcinoma (HNSCC) has a poor clinical outcome despite the presence of a rich CD8+ T cell tumor infiltrate in the majority of patients. This may be due to alterations of tumor infiltrating CD8+ T cells. Here, we performed a characterization of HNSCC infiltrating CD8+ T cells in a cohort of 30 patients. The results showed that differential intratumoral frequency of CD8+CD28+ T cells, CD8+CD28- T cells, and CD8+CD28-CD127-CD39+ Treg distinguished between HNSCC patients who did or did not respond to treatment. Moreover, high PD1 expression identified a CD8+CD28- T cell subpopulation, phenotypically/functionally corresponding to CD8+CD28-CD127-CD39+ Treg, which showed a high expression of markers of exhaustion. This observation suggests that development of exhaustion and acquisition of regulatory properties may configure the late differentiation stage for intratumoral effector T cells, a phenomenon we define as effector-to-regulatory T cell transition.
Identifiants
pubmed: 34066538
pii: cancers13092234
doi: 10.3390/cancers13092234
pmc: PMC8124419
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : Fondi 5x1000 2016
Références
Cancer Res. 2003 May 15;63(10):2546-52
pubmed: 12750278
Pathology. 2016 Feb;48(2):177-87
pubmed: 27020390
Clin Cancer Res. 2013 Apr 1;19(7):1816-26
pubmed: 23401227
Hum Immunol. 2004 Feb;65(2):142-56
pubmed: 14969769
Clin Cancer Res. 2016 Jan 1;22(1):158-66
pubmed: 26253870
J Immunother Cancer. 2018 Sep 4;6(1):87
pubmed: 30180905
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Int J Oncol. 2009 Mar;34(3):629-39
pubmed: 19212667
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):469-477
pubmed: 32184121
Cancer Res. 2018 Jan 1;78(1):115-128
pubmed: 29066514
Anticancer Res. 2005 Nov-Dec;25(6C):4435-8
pubmed: 16334122
J Immunol Res. 2016;2016:8941260
pubmed: 27314056
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Immunol. 2007 Oct 1;179(7):4323-34
pubmed: 17878327
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
Curr Hematol Malig Rep. 2019 Aug;14(4):286-291
pubmed: 31187421
Int J Mol Sci. 2019 Jun 08;20(11):
pubmed: 31181772
Med Oncol. 2019 Mar 29;36(5):42
pubmed: 30927146
Int J Cancer. 2016 Jan 1;138(1):171-81
pubmed: 26178914
J Natl Cancer Inst. 2019 Jul 1;111(7):655-663
pubmed: 30912808
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Prostate. 2014 Oct;74(14):1452-61
pubmed: 25111810
Front Oncol. 2019 Aug 29;9:827
pubmed: 31555588
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33593828
PLoS One. 2012;7(6):e38711
pubmed: 22701698
Ann Surg Oncol. 2012 Aug;19(8):2506-14
pubmed: 22411204
Front Immunol. 2018 Aug 15;9:1904
pubmed: 30158938
Pathology. 2017 Jun;49(4):397-404
pubmed: 28427753
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Front Oncol. 2020 Jan 10;9:1470
pubmed: 31998639
Cancer Res. 2012 Mar 1;72(5):1070-80
pubmed: 22266112
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Virchows Arch. 2014 Sep;465(3):299-312
pubmed: 25027580
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cancer Immunol Immunother. 2013 May;62(5):851-62
pubmed: 23359087
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987257
Semin Radiat Oncol. 2018 Jan;28(1):12-16
pubmed: 29173750
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
J Neuroimmunol. 2007 Sep;189(1-2):50-8
pubmed: 17675252
Hum Immunol. 2008 Nov;69(11):745-50
pubmed: 18832002
Br J Cancer. 2014 Jan 21;110(2):501-9
pubmed: 24129245
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Oncoimmunology. 2017 Jan 3;6(2):e1273309
pubmed: 28344887
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33023982
Science. 2012 Nov 30;338(6111):1220-5
pubmed: 23197535
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Clin Otolaryngol. 2018 Oct;43(5):1312-1320
pubmed: 29896922
Curr Treat Options Oncol. 2019 Apr 22;20(5):43
pubmed: 31011837
Ann Oncol. 2010 May;21 Suppl 5:v184-6
pubmed: 20555077
Hum Pathol. 2018 Dec;82:104-112
pubmed: 30036594
Immunol Rev. 2018 May;283(1):194-212
pubmed: 29664561
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544